Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Male and female subjects greater than or equal to 18 years of age

• Overactive bladder symptoms for at least 3 months

• Previously treated with antimuscarinic OAB medications

Exclusion Criteria:

• Participation in any professionally coached sessions (RN, NP, PA or PT) teaching behavioral interventions